Vancomycin derivatives active against resistant bacterial nosocomial infections [ 2010 - 2012 ]

Research Grant

Researchers: Prof Matthew Cooper (Principal investigator) ,  Prof David Paterson

Brief description Bacterial infection is a leading cause of death worldwide and the emergence of superbugs that are resistant to multiple treatments is becoming a major global concern. Vancomycin is the drug of last resort for the treatment of hospital-acquired Gram -positive bacterial infections. We will synthetically modify vancomycin by incorporating naturally occurring membrane-associative peptides to produce novel antibiotics with multiple modes of action to avoid existing bacterial resistance mechanisms.

Funding Amount $AUD 760,763.22

Funding Scheme NHMRC Project Grants

Notes Standard Project Grant